CN117462620A - Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof - Google Patents
Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof Download PDFInfo
- Publication number
- CN117462620A CN117462620A CN202310772286.4A CN202310772286A CN117462620A CN 117462620 A CN117462620 A CN 117462620A CN 202310772286 A CN202310772286 A CN 202310772286A CN 117462620 A CN117462620 A CN 117462620A
- Authority
- CN
- China
- Prior art keywords
- parts
- lung cancer
- traditional chinese
- chinese medicine
- treating lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 75
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 52
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 52
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 244000104272 Bidens pilosa Species 0.000 claims abstract description 9
- 235000010662 Bidens pilosa Nutrition 0.000 claims abstract description 9
- 244000281702 Dioscorea villosa Species 0.000 claims abstract description 8
- 241000893536 Epimedium Species 0.000 claims abstract description 8
- 241000132446 Inula Species 0.000 claims abstract description 8
- 235000018905 epimedium Nutrition 0.000 claims abstract description 8
- 241000906579 Actaea cimicifuga Species 0.000 claims abstract description 7
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 7
- 241000951473 Schizonepeta Species 0.000 claims abstract description 7
- 244000277583 Terminalia catappa Species 0.000 claims abstract description 7
- 235000011517 Terminalia chebula Nutrition 0.000 claims abstract description 7
- 235000006533 astragalus Nutrition 0.000 claims abstract description 7
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000009835 boiling Methods 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 9
- 239000012498 ultrapure water Substances 0.000 claims description 9
- 229940104299 cimicifugae rhizoma Drugs 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 7
- 239000009636 Huang Qi Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000002344 surface layer Substances 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 229940088679 drug related substance Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 210000004072 lung Anatomy 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 13
- 210000003734 kidney Anatomy 0.000 abstract description 12
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 230000001717 pathogenic effect Effects 0.000 abstract description 10
- 208000026435 phlegm Diseases 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000004087 circulation Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 6
- 230000004614 tumor growth Effects 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000005728 strengthening Methods 0.000 abstract description 4
- 238000012404 In vitro experiment Methods 0.000 abstract description 3
- 230000008506 pathogenesis Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical group N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 7
- 229960004316 cisplatin Drugs 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 241001061264 Astragalus Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 210000004233 talus Anatomy 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 240000002262 Litsea cubeba Species 0.000 description 1
- 235000012854 Litsea cubeba Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000001522 Terminalia chebula Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine formula for treating lung cancer, a preparation method and application thereof, wherein the traditional Chinese medicine formula comprises the following raw materials in parts by weight: 13-16 parts of astragalus membranaceus, 7-10 parts of epimedium herb, 7-10 parts of inula flower, 7-10 parts of cimicifuga foetida, 7-10 parts of Ningpo Yam rhizome, 7-10 parts of myrobalan, 13-16 parts of spanishneedles herb, 7-10 parts of schizonepeta herb and 7-10 parts of fructus psoraleae. The traditional Chinese medicine composition is developed based on lung cancer pathogenesis and on the basis of theoretical arrangement research of a triple-jiao system and laboratory research, has the functions of tonifying lung and kidney, promoting qi circulation, resolving phlegm, removing blood stasis, detoxifying and inhibiting tumor growth, and has good effects on treating lung cancer. The general treatment is strengthening body resistance to eliminate pathogenic factors, treating the method of tonifying lung and kidney, promoting qi circulation to resolve phlegm, removing blood stasis and detoxifying. Experiments prove that the Chinese medicinal composition has good anti-lung cancer effect in vivo and in vitro experiments, has low toxicity, and is a great innovation for treating lung cancer.
Description
Technical Field
The invention relates to a traditional Chinese medicine formula for treating lung cancer, a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines.
Background
Lung cancer is a malignant tumor of the bronchial mucosa or glands, the incidence and mortality rate of which grow very fast, and has become one of the most threatening malignant tumors for the health and life of people. Because of the limitations of Western medicine treatment means such as surgery, chemotherapy, targeted therapy, immunotherapy and the like, the traditional Chinese and Western medicine combination therapy is a main method for treating the domestic lung cancer at present, but most of the common lung cancer treatment formulas are complex in formula, and the extraction process is complex, so that the medicine cost is high, the effect is slow, and great economic burden is brought to patients. According to the development research, the inventor finally forms a traditional Chinese medicine formula special for simple medicine through repeated investigation and verification, is hopeful to achieve better treatment effect and brings more economic and practical treatment means.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a traditional Chinese medicine formula for treating lung cancer, and a preparation method and application thereof, thereby playing a role in clinical diagnosis and treatment and prevention of lung cancer, reducing the death rate of lung cancer patients, prolonging the survival time and improving the life quality of patients.
In order to achieve the above object, one of the technical solutions of the present invention is:
a traditional Chinese medicine formula for treating lung cancer comprises the following raw materials in parts by weight: 13-16 parts of astragalus membranaceus, 7-10 parts of epimedium herb, 7-10 parts of inula flower, 7-10 parts of cimicifuga foetida, 7-10 parts of Ningpo Yam rhizome, 7-10 parts of myrobalan, 13-16 parts of spanishneedles herb, 7-10 parts of schizonepeta herb and 7-10 parts of fructus psoraleae.
One of the technical schemes of the invention is as follows: a preparation method of a traditional Chinese medicine formula for treating lung cancer comprises the following steps:
(1) Slicing radix astragali, cimicifugae rhizoma, and rhizoma Dioscoreae Nipponicae, and adding flos Inulae, herba Epimedii, fructus Chebulae, fructus Psoraleae, herba Bidentis Bipinnatae, and herba Schizonepetae;
(2) Adding ethanol solution, soaking at room temperature in dark, filtering, removing ethanol from the filtrate by rotary evaporator, drying to solid, and pulverizing into powder;
(3) Placing the residue after filtration into a pot, adding ultrapure water, boiling with strong fire, concentrating the liquid medicine with small fire and slight boiling until the water is not seen in the surface layer residue, taking out the liquid medicine, suction filtering, discarding the residue, drying the filtrate into solid, and pulverizing into powder;
(4) Mixing the powders obtained in the steps (2) and (3).
Further, the volume concentration of the ethanol solution in the step (2) is 70-75%, and the dosage is 8-12 times of the volume of the bulk drug.
Further, soaking in the step (2) for 6-10 days.
Further, the evaporation temperature of the rotary evaporator in the step (2) is 42-50 ℃.
Further, the amount of ultrapure water used in the step (3) is 8-15 times the volume of the dregs.
Further, in the step (4), the powder in the step (2) and the powder in the step (3) are mixed according to the weight ratio of 1:2-4.
One of the technical schemes of the invention is as follows: an application of the traditional Chinese medicine composition in preparing medicines for treating lung cancer.
Pharmacological effects of the raw materials:
astragalus root, radix astragali, slightly warm in nature, sweet in taste; enter spleen and lung meridians. The main effects are as follows: invigorating spleen and replenishing middle warmer, raising yang and lifting sinking, tonifying and strengthening the exterior, promoting urination, expelling toxin and promoting granulation.
Epimedium herb is warm in nature and sweet in flavor; enter kidney meridian and liver meridian. The main effects are as follows: kidney yang, strengthening tendons and bones, and dispelling pathogenic wind.
Inula flower, slightly warm nature, bitter, pungent and salty taste; enter lung, spleen, stomach and large intestine meridians. The main effects are as follows: descending qi, resolving phlegm, promoting the circulation of water and arresting vomiting.
Cimicifugae rhizoma, slightly cold in nature, pungent and sweet in taste; it enters lung, spleen, large intestine and stomach meridians. The main effects are as follows: promoting eruption, clearing heat and detoxicating, and raising yang.
Chuanlong Yam, is warm in nature, sweet and bitter in taste; it enters liver, kidney and lung meridians. The main effects are as follows: dispelling wind and removing dampness, relaxing tendons and dredging collaterals, promoting blood circulation and relieving pain, and relieving cough and asthma.
Chebula fruit, flat in nature, sour and bitter in taste; enter lung and large intestine meridians. The main effects are as follows: astringing lung, astringing intestine and descending qi.
Bidens pilosa is warm in nature and bitter in taste; it enters meridians of liver, kidney and spleen. The main effects are as follows: clearing away heat and toxic materials, eliminating dampness, eliminating pathogenic wind, promoting blood circulation, and removing blood stasis.
Herba Schizonepetae, slightly warm, pungent in flavor; it enters lung and liver meridians. The main effects are as follows: relieving exterior syndrome, dispelling pathogenic wind, promoting eruption and eliminating sore.
Fructus Psoraleae, warm nature, pungent, bitter and warm; enter kidney and spleen meridians. The main effects are as follows: warming kidney, tonifying yang, receiving qi, and relieving diarrhea.
The traditional Chinese medicine is used for recognizing lung cancer, which belongs to the category of cancer diseases, and is mainly caused by viscera dysfunction, qi and blood body fluid dysfunction, lung failure in dispersing and descending due to factors such as deficiency of vital qi, exogenous pathogenic toxin, internal injury seven emotions, eating disorder, old diseases and the like, so that qi stagnation, blood stasis, phlegm coagulation, phlegm stasis, toxin brewing and heat stagnation in viscera, mutual pulsation and long-term disease are caused.
The triple energizer is the other cause of primordial qi, and can transport the primordial qi stored in the kidney to the whole body to stimulate the functional activities of the viscera and tissues. Based on the system research results of the team on the triple energizer, the qi is adopted as the basis of primordial qi; the transportation and transformation of water is the principal function of the triple energizer, while the lung cancer is the principal pathogenesis of deficiency and qi stagnation, and the stagnation of body fluids and blood can be treated by the triple energizer theory. The astragalus root is used as a monarch, the lung qi is tonified, the healthy qi is supported, the stagnation is removed, the arthralgia is removed, and the toxin is removed; herba Epimedii and fructus Psoraleae serve as ministerial drugs, and invigorate primordial qi to promote lung qi generation and enhance healthy qi; chuanlong Yam has the functions of promoting blood circulation to remove meridian obstruction, clearing lung-heat and resolving phlegm as ministers; the spanishneedles herb has the functions of clearing heat and detoxicating, and removing stasis and detumescence; cimicifugae rhizoma and Inulae flos can assist qi and ascend to disperse pathogenic factors, and can assist qi and descend to disperse water, so that qi stagnation is removed, water is circulated, and the source of phlegm and blood stasis is broken; herba Schizonepetae and fructus Chebulae can disperse stagnancy to eliminate pathogenic factors, astringe lung qi to strengthen vital qi, eliminate pathogenic factors and protect vital qi; the lung-fit property is recovered and the lung-fit property is recovered; one-time dispersion and one-time collection, eliminating pathogenic toxin without hurting body resistance; the four herbs are combined together as adjuvant and ministerial drugs. Has the effects of tonifying lung and kidney, promoting qi circulation, resolving phlegm, removing blood stasis and detoxifying.
Advantageous effects
The traditional Chinese medicine composition is developed based on lung cancer pathogenesis and on the basis of theoretical arrangement research of a triple-jiao system and laboratory research, has the functions of tonifying lung and kidney, promoting qi circulation, resolving phlegm, removing blood stasis, detoxifying and inhibiting tumor growth, and has good effects on treating lung cancer. The general treatment is strengthening body resistance to eliminate pathogenic factors, treating the method of tonifying lung and kidney, promoting qi circulation to resolve phlegm, removing blood stasis and detoxifying. Experiments prove that the Chinese medicinal composition has good anti-lung cancer effect in vivo and in vitro experiments, has low toxicity, and is a great innovation for treating lung cancer.
Drawings
FIG. 1 shows the effect of a traditional Chinese medicine formulation on the apparent state of tumor cells.
FIG. 2 shows the growth inhibition rate of the traditional Chinese medicine formulation on tumor cells.
Detailed Description
The following describes the embodiments of the present invention in further detail with reference to examples.
Example 1
A traditional Chinese medicine formula for treating lung cancer comprises the following raw materials in parts by weight: 13 parts of astragalus, 7 parts of epimedium, 7 parts of inula flower, 7 parts of cimicifuga foetida, 7 parts of Ningpo Yam rhizome, 7 parts of myrobalan, 13 parts of sticktight, 7 parts of schizonepeta, and 7 parts of fructus psoraleae.
The preparation method comprises the following steps:
(1) Slicing radix astragali, cimicifugae rhizoma, and rhizoma Dioscoreae Nipponicae, and adding flos Inulae, herba Epimedii, fructus Chebulae, fructus Psoraleae, herba Bidentis Bipinnatae, and herba Schizonepetae;
(2) Adding 10 times of the volume of the raw materials, and soaking in 75% ethanol solution; at room temperature, covering with preservative film and tinfoil paper, keeping in dark, stirring and shaking twice a day with a glass rod, and soaking for 7 days; then three layers of gauze cover the bottle mouth, pour out the leaching solution, three layers of filter paper are used for filtering, an external suction pump is connected for accelerating the filtering speed, the filtrate is evaporated at 45 ℃ by using a rotary evaporator to remove ethanol in the filtrate, and finally the filtrate is dried into solid by adopting a conventional low-temperature negative pressure method and is crushed into powder for preservation at-20 ℃;
(3) Placing the residue after filtration into a pot, adding ultrapure water 15 times of the volume of the residue, placing on an electromagnetic oven, boiling with strong fire, then concentrating the liquid medicine with small fire and slight boiling, taking out the liquid medicine when the surface layer residue cannot see obvious moisture, carrying out suction filtration, discarding the residue, placing the filtrate into an evaporation dish, drying into solid by adopting a conventional low-temperature negative pressure method, pulverizing into powder, and preserving at-20 ℃;
(4) Mixing the powders obtained in the steps (2) and (3) according to the weight ratio of 1:3.
Example 2
A traditional Chinese medicine formula for treating lung cancer comprises the following raw materials in parts by weight: 14 parts of astragalus, 8 parts of epimedium, 8 parts of inula flower, 8 parts of cimicifuga foetida, 8 parts of Ningpo Yam rhizome, 8 parts of myrobalan, 14 parts of sticktight, 8 parts of schizonepeta, and 8 parts of fructus psoraleae.
The preparation method comprises the following steps:
(1) Slicing radix astragali, cimicifugae rhizoma, and rhizoma Dioscoreae Nipponicae, and adding flos Inulae, herba Epimedii, fructus Chebulae, fructus Psoraleae, herba Bidentis Bipinnatae, and herba Schizonepetae;
(2) Adding 8 times of the volume of the raw materials, and soaking in 75% ethanol solution; at room temperature, covering with preservative film and tinfoil paper, keeping in dark, stirring and shaking twice a day with a glass rod, and soaking for 6 days; then three layers of gauze cover the bottle mouth, pour out the leaching solution, three layers of filter paper are used for filtering, an external suction pump is connected for accelerating the filtering speed, the filtrate is evaporated by a rotary evaporator at 42 ℃ to remove ethanol in the filtrate, and finally the filtrate is dried into solid by a conventional low-temperature negative pressure method and crushed into powder for preservation at-20 ℃;
(3) Placing the residue after filtration into a pot, adding ultrapure water 10 times of the volume of the residue, placing on an electromagnetic oven, boiling with strong fire, then concentrating the liquid medicine with small fire and slight boiling, taking out the liquid medicine when the surface layer residue cannot see obvious moisture, carrying out suction filtration, discarding the residue, placing the filtrate into an evaporation dish, drying into solid by adopting a conventional low-temperature negative pressure method, pulverizing into powder, and preserving at-20 ℃;
(4) Mixing the powders obtained in the steps (2) and (3) according to the weight ratio of 1:2.
Example 3
A traditional Chinese medicine formula for treating lung cancer comprises the following raw materials in parts by weight: 15 parts of astragalus, 9 parts of epimedium, 9 parts of inula flower, 9 parts of cimicifuga foetida, 9 parts of Ningpo Yam rhizome, 9 parts of myrobalan, 15 parts of sticktight, 9 parts of schizonepeta, and 9 parts of fructus psoraleae.
The preparation method comprises the following steps:
(1) Slicing radix astragali, cimicifugae rhizoma, and rhizoma Dioscoreae Nipponicae, and adding flos Inulae, herba Epimedii, fructus Chebulae, fructus Psoraleae, herba Bidentis Bipinnatae, and herba Schizonepetae;
(2) Adding 12 times of the volume of the raw materials, and soaking in 70% ethanol solution; at room temperature, covering with preservative film and tinfoil paper, keeping in dark, stirring and shaking twice a day with a glass rod, and soaking for 10 days; then three layers of gauze cover the bottle mouth, pour out the leaching solution, three layers of filter paper are used for filtering, an external suction pump is connected for accelerating the filtering speed, the filtrate is evaporated by a rotary evaporator at 50 ℃ to remove ethanol in the filtrate, and finally the filtrate is dried into solid by a conventional low-temperature negative pressure method and crushed into powder for preservation at-20 ℃;
(3) Placing the residue after filtration into a pot, adding ultrapure water with the volume of 12 times of that of the residue, placing on an electromagnetic oven, boiling with strong fire, then concentrating the liquid medicine with small fire and slight boiling, taking out the liquid medicine when no obvious moisture is seen in the surface layer residue, carrying out suction filtration, discarding the residue, placing the filtrate into an evaporation dish, drying into solid by adopting a conventional low-temperature negative pressure method, pulverizing into powder, and preserving at-20 ℃;
(4) Mixing the powders obtained in the steps (2) and (3) according to the weight ratio of 1:4.
Example 4
A traditional Chinese medicine formula for treating lung cancer comprises the following raw materials in parts by weight: 16 parts of astragalus, 10 parts of epimedium, 10 parts of inula flower, 10 parts of cimicifuga foetida, 10 parts of Ningpo Yam rhizome, 10 parts of myrobalan, 16 parts of sticktight, 10 parts of schizonepeta, and 10 parts of fructus psoraleae.
(1) Slicing radix astragali, cimicifugae rhizoma, and rhizoma Dioscoreae Nipponicae, and adding flos Inulae, herba Epimedii, fructus Chebulae, fructus Psoraleae, herba Bidentis Bipinnatae, and herba Schizonepetae;
(2) Adding 10 times of the volume of the raw materials, and soaking in 75% ethanol solution; at room temperature, covering with preservative film and tinfoil paper, keeping in dark, stirring and shaking twice a day with a glass rod, and soaking for 7 days; then three layers of gauze cover the bottle mouth, pour out the leaching solution, three layers of filter paper are used for filtering, an external suction pump is connected for accelerating the filtering speed, the filtrate is evaporated at 45 ℃ by using a rotary evaporator to remove ethanol in the filtrate, and finally the filtrate is dried into solid by adopting a conventional low-temperature negative pressure method and is crushed into powder for preservation at-20 ℃;
(3) Placing the residue after filtration into a pot, adding ultrapure water 10 times of the volume of the residue, placing on an electromagnetic oven, boiling with strong fire, then concentrating the liquid medicine with small fire and slight boiling, taking out the liquid medicine when the surface layer residue cannot see obvious moisture, carrying out suction filtration, discarding the residue, placing the filtrate into an evaporation dish, drying into solid by adopting a conventional low-temperature negative pressure method, pulverizing into powder, and preserving at-20 ℃;
(4) Mixing the powders obtained in the steps (2) and (3) according to the weight ratio of 1:3.
Anti-lung cancer traditional Chinese medicine formula tumor growth inhibition experiment:
1 Material
1.1 cell lines
Human lung cancer cell line a549; mouse lung cancer cell line LLC (all purchased from cell center of national academy of medical science).
1.2 animals
C57BL/6 mice, 4-6 weeks old, available from Beijing Bei Fu Biotechnology Co.
2 method
2.1 cell culture
Human lung cancer cell A549 was grown in DMEM medium containing 10% (v/v) fetal bovine serum at 37deg.C in 5% CO 2 Incubator, medium was changed every 48 h.
2.2 mouse feeding
SPF-level constant temperature animal house, room 1 time/day ultraviolet irradiation that feeds, the personnel of going in and out are strictly controlled, entry is gone in, export is gone out, changes clean working clothes before every business turn over, and the mouse fodder is vacuum packaging irradiation fodder, and the pad is the corncob pad that is through irradiation Co60 disinfection, and drinking water is distilled water, and fodder, pad and water are all 1 time/3 day to be changed, guarantee its sufficient diet, quiet clean comfortable living environment.
2.3 observation of growth states of lung cancer cells A549 in Normal group and traditional Chinese group
2.1 cell culture to logarithmic growth phase, when the area of the petri dish was covered by more than 70%, digestion was carried out with a digestion solution (0.02% by mass of ethylenediamine tetraacetic acid disodium salt (EDTA) and 0.25% by mass of trypsin were formulated in a volume ratio of 1:1), and inoculated into 6-well plates at a density of 30 ten thousand cells/2.5 mL/well. After 24h growth, the medium in the wells was discarded, and 3 wells of each of the blank and the drug group (the drug formulation of example 1) were set, and the blank was directly added with a content of 10% (v)V) DMEM medium with fetal bovine serum, 2.5 mL/well, IC screened according to 2.4 with drug group 30 (drug concentration at inhibition rate of 30%) and DMEM medium containing 80 μg/mL of 10% (v/v) fetal bovine serum was added at 2.5 mL/well; culturing for 48h, taking out, observing, and photographing and recording.
2.4 determination of the cell growth inhibition dose-Effect relationship by MTT method
Human lung cancer cell line A549 was 1X 10 4 Cells/200. Mu.L/well were inoculated into 96-well planar culture plates, respectively, at 37℃and 5% CO 2 Saturated humidity CO 2 The incubator cultures for 24 hours. After 24h, the cells were grown completely adherent, medium in wells was discarded, control and 5 groups of traditional Chinese medicine were set, 3 duplicate wells were placed, 200. Mu.L of DMEM medium containing 10% (v/v) fetal bovine serum was added to the control group, 200. Mu.L of the traditional Chinese medicine extracts (example 1, solvent was DMEM medium containing 10% (v/v) fetal bovine serum) were added to the 5 groups of traditional Chinese medicine at concentrations of 25, 50, 75, 100, 150. Mu.g/mL, respectively, and slow addition was noted depending on the walls of the wells. Culture was continued for 48 hours, the culture supernatant was removed, 100mL of MTT (0.5 mg/mL) was added to each well, culture was continued for 2 hours, the supernatant was carefully aspirated off, and 100. Mu.L of dimethyl sulfoxide (DMSO) was added to dissolve the purple precipitate, and the OD was measured at a wavelength of 490nm (/ 570 nm) using an microplate reader. According to the formula:
inhibition (%) = (1-average a of chinese medicine pores) 490/570 value Average A of control wells 490/570 value )×100％
IC 30 Calculation of the values: repeating the above experiment for more than three times, introducing the obtained experimental data (inhibition rate) into Excel table, inserting into scatter diagram to generate trend line, and calculating IC according to trend line equation 30 Values.
2.5 Effect of Chinese medicinal formula on LLC Lung cancer cell transplantation tumor mice
LLC cells were removed from the liquid nitrogen tank, quickly thawed and removed to 10mL of DMEM medium containing 5% (v/v) fetal bovine serum, and transferred to three to five generations of later dish expansion culture. Taking LLC cells in logarithmic growth phase, digesting with pancreatin, centrifuging, and adjusting cell concentration to 1×10 7 And each mL. The experiments were divided into a blank group, a model group, a low-dose traditional Chinese medicine group, a high-dose traditional Chinese medicine group and a cisplatin group, and 8 mice in each group. Blank group right of each mouseThe right anterior axilla of each other group of mice is injected with 0.15mL of LLC cell suspension to construct an LLC lung cancer transplantation tumor mouse model. After one week, soybean grain-like tumor bodies can be observed or touched at the right armpit of the molding mouse, and the molding is successful. After the molding is successful, the stomach infusion medication is carried out on the traditional Chinese medicine group and the cisplatin group, and the medication dosage is calculated once a day: firstly, the equivalent dose of the mice is calculated to be 1.1g/kg according to a body surface area method. Low-dose group lavage 1.1g/kg, high-dose group lavage 3.3g/kg,0.1mL/10g; the cisplatin group is injected into the abdominal cavity with 2mg/kg (the solvent is normal saline/ultrapure water) and 0.1mL/10g; the model group and the blank group are irrigated with the same amount of physiological saline as a control. Tumor volume measurements were made every 5 days, after 3 weeks of drug administration, mice were sacrificed by cervical vertebrae removal, tumor bodies were removed, final tumor volumes of mice were measured and tumor suppression rates were calculated.
Tumor volume and drug tumor inhibition rate: the longest diameter L (mm) and the largest transverse diameter W (mm) of the tumor in the vertical direction are measured by a vernier caliper, and the method is carried out according to the Litsea method: v (mm) 3 )＝L×W 2 Tumor volume was calculated.
Tumor inhibition rate = (1-average tumor volume of administration group/average tumor volume of model group) ×100%
2.6 general observations of LLC Lung cancer transplantable tumor mice
2.5 after starting the intragastric administration, general observations and recordings were made every three days. The main observations include: body conformation, hair color and luster, eye brightness, light irritation, observation of its perception and response to the external environment, sensitivity to activity, etc.
2.7 statistical method
The metrology data application software spss 25.0 performs one-way analysis of variance and applies the software to perform correlation analysis and curve fitting.
3 results of experiments
3.1 Effect of Chinese medicinal composition on growth and morphology of human Lung cancer cell Strain A549
Observing under a microscope, the blank group cells grow in an adherent way, the cell limit is clear, the nuclear division phase is obvious, and the pseudopodia extends out; the outline of the cells of the drug administration group is very obvious, the cytoplasm is extremely rough, a large amount of granular substances are filled in, and a blank field of vision of necrosis appears in a large range along with the increase of the concentration of the drug (see figure 1). This indicates that tumor cells became worse and even die as a tablet after administration.
3.2 influence of the Chinese medicinal composition on the growth of tumor cells (inhibition Rate)
The Chinese medicine can inhibit the growth of human lung cancer cell strain A549, and the Chinese medicine has dose-effect dependency on cell growth inhibition with the increase of medicine concentration (see table 1 and figure 2). At the same time, it is known that IC 30 The value was 80. Mu.g/mL.
Table 1: the growth inhibition rate of the Chinese medicine on tumor cells is changed along with the concentration of the medicine (unit: mu g/mL)
3.3 inhibiting effect of Chinese medicinal composition on proliferation of LLC lung cancer transplantable tumor
About 7 days are required from inoculation to tumor formation, the tumor body grows slowly in the initial stage of inoculation, and when the tumor body grows rapidly about 12 days of inoculation. The high and low dose groups of the traditional Chinese medicine have certain effect of inhibiting tumor growth and certain dose dependency, wherein the high dose group has better effect than the cisplatin group (see table 2).
Table 2: influence of traditional Chinese medicine on lung cancer transplantable tumor volume
". Times." indicates that P < 0.05 compared to model group; "# indicates that P < 0.05 compared to the low dose group.
3.4 Effect of traditional Chinese medicine formulation on general conditions of LLC Lung cancer transplantable tumor mice
No death occurred in each group of animals throughout the experiment. The hair of the model group and the cisplatin group is withered and matt in color, emaciated, listlessness, dull eyes and bowstring; the hair color of the low-dose traditional Chinese medicine group, the high-dose traditional Chinese medicine group and the blank group is bright and smooth, the eyes are with spirit, and the activities are sensitive. The animal activity sensitivity is as follows from high to low in sequence: high-dose traditional Chinese medicine group > low-dose traditional Chinese medicine group > cisplatin group > model group. These results show that compared with cisplatin, the traditional Chinese medicine composition can improve the growth and living state of mice and the life quality no matter the dosage is high or low.
Conclusion 4
4.1 in vitro experiments of the lung cancer resisting traditional Chinese medicine composition show good lung cancer resisting effect and dose dependency.
4.2 the traditional Chinese medicine prescription for resisting lung cancer can well inhibit the growth of mouse lung cancer cell LLC transplantation tumor, is dose-dependent, and can reduce the effects of emaciation, listlessness, activity weakening and the like caused by lung cancer; and has good curative effect on inhibiting tumor growth.
4.3 the traditional Chinese medicine composition for resisting lung cancer has good lung cancer resisting effect and small toxicity, is innovation in medicines for treating lung cancer, and has obvious clinical significance.
Claims (8)
1. The traditional Chinese medicine formula for treating lung cancer is characterized by comprising the following raw materials in parts by weight: 13-16 parts of astragalus membranaceus, 7-10 parts of epimedium herb, 7-10 parts of inula flower, 7-10 parts of cimicifuga foetida, 7-10 parts of Ningpo Yam rhizome, 7-10 parts of myrobalan, 13-16 parts of spanishneedles herb, 7-10 parts of schizonepeta herb and 7-10 parts of fructus psoraleae.
2. A method for preparing a traditional Chinese medicine formula for treating lung cancer according to claim 1, which is characterized by comprising the following steps:
(1) Slicing radix astragali, cimicifugae rhizoma, and rhizoma Dioscoreae Nipponicae, and adding flos Inulae, herba Epimedii, fructus Chebulae, fructus Psoraleae, herba Bidentis Bipinnatae, and herba Schizonepetae;
(2) Adding ethanol solution, soaking at room temperature in dark, filtering, removing ethanol from the filtrate by rotary evaporator, drying to solid, and pulverizing into powder;
(3) Placing the residue after filtration into a pot, adding ultrapure water, boiling with strong fire, concentrating the liquid medicine with small fire and slight boiling until the water is not seen in the surface layer residue, taking out the liquid medicine, suction filtering, discarding the residue, drying the filtrate into solid, and pulverizing into powder;
(4) Mixing the powders obtained in the steps (2) and (3).
3. The method according to claim 2, wherein the ethanol solution in the step (2) has a volume concentration of 70-75% and is used in an amount of 8-12 times the volume of the drug substance.
4. The method according to claim 2, wherein the soaking is performed in step (2) for 6 to 10 days.
5. The method according to claim 2, wherein the evaporation temperature of the rotary evaporator in step (2) is 42 to 50 ℃.
6. The method according to claim 2, wherein the amount of ultrapure water used in the step (3) is 8 to 15 times the volume of the residue.
7. The method according to claim 2, wherein the powder of step (2) and the powder of step (3) are mixed in a weight ratio of 1:2-4 in step (4).
8. Use of the traditional Chinese medicine composition according to claim 1 in preparing medicines for treating lung cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310772286.4A CN117462620A (en) | 2023-06-28 | 2023-06-28 | Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310772286.4A CN117462620A (en) | 2023-06-28 | 2023-06-28 | Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117462620A true CN117462620A (en) | 2024-01-30 |
Family
ID=89631845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310772286.4A Pending CN117462620A (en) | 2023-06-28 | 2023-06-28 | Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117462620A (en) |
-
2023
- 2023-06-28 CN CN202310772286.4A patent/CN117462620A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104187172B (en) | Functional feed for treating enterogastritis diseases of turtles and preparation method of functional feed | |
| CN105617316A (en) | Antibacterial disinfectant for clinical laboratory and preparation method | |
| CN103536826B (en) | One is treated colpitic Chinese medicine composition and preparation method thereof | |
| CN107158223A (en) | For clearing heat and detoxicating Chinese medicine preparation with anti-inflammatory and preparation method thereof | |
| CN108567820A (en) | A kind of Chinese medicine composition and preparation method thereof for oncotherapy | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN105056159A (en) | Medicine for treating parasitic diseases of pigs and preparation method thereof | |
| CN105535495B (en) | A kind of Chinese medicine composition and preparation method of the element culturing fixed folder treatment cancer of the esophagus | |
| WO2018171672A1 (en) | Anti-cancer pharmaceutical composition and use thereof | |
| CN104548049A (en) | Traditional Chinese medicine composition for treating senile osteoporosis and preparation method thereof | |
| CN117462620A (en) | Traditional Chinese medicine formula for treating lung cancer and preparation method and application thereof | |
| CN104189413A (en) | Medicine composition for treating enterogastritis diseases of turtles and preparation method of medicine composition | |
| CN108041088A (en) | A kind of clinical laboratory's Traditional Chinese medicine air disinfectant and preparation method thereof | |
| CN107149653A (en) | A kind of Traditional Chinese medicine compound composition with antitumor activity and its preparation method and application | |
| CN105056078A (en) | Traditional Chinese medicine composition for treating stomach fire exuberance, toothache and ozostomia | |
| CN104839483A (en) | Mixed feed for soft-shelled turtles of 2-3 years old and preparation method thereof | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN110051759A (en) | A kind of Chinese medicinal composition preparation and preparation method thereof for treating liver cancer | |
| CN112076305A (en) | A Chinese medicinal oral and topical stock solution mixture for treating metabolic syndrome and resisting bacteria and inflammation | |
| CN104840747B (en) | Chinese medicine composition with antithyroid cancer activity and its preparation method and application | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN102526248B (en) | Traditional Chinese medicine prescription capable of curing diabetes wound fester and continuously reducing blood sugar | |
| CN114470140B (en) | Traditional Chinese medicine composition for preventing and treating gastric cancer as well as preparation method and application thereof | |
| CN105596407A (en) | Pharmaceutical composition for treating pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |